A research institution
A research organization
Unlike many stem cell treatment clinics, Beike itself is a dedicated research organization. Our vigor for helping patients extends far beyond simply using stem cells for clinical treatments based on other’s research. Beike extends its actual scientific research into cell technologies, and Beike has been one of the world leaders in this important research. This allows Beike’s treatment protocols and stem cell processing to not only be guided by 3rd party research, but also their own. Beike has almost 50 published peer-reviewed research papers in scientific journals around the world (such as Nature) and has spent tens of millions over the past decade on scientific laboratories and cell research.
Global Clinical Research Technical Support Network:
Beike Biotech has been cooperating with more than 400 domestic and foreign scientific and medical institutions to provide individualized cell preparation technologies for cell therapy of more than 80,000 patients with refractory diseases, including those from the United States, Canada, the United Kingdom, Japan and so on more than 70 countries. The significant treatment results are highly recognized by the international academic community.
Advanced immune cell therapy technology:
Through strategic licensing, mergers and acquisitions, independent research and development, Beike Biotechnology account for an important strategic position in the field of immunotherapy. Beike has a variety of international advanced immunotherapy technology and products. ALT803 is considered by NCI to be the most promising interleukin-based drug to cure cancer. In the development of antibodies to major histocompatibility complex (RBC) receptor-recognition R & D platforms, MCAR-T and MCAR-NK cell therapies are more effective than the conventional CAR-T, TCR-T and bispecific antibodies in hematological malignancies, solid tumors and viral infections and other diseases.
Integrated Cell Bank and Regional Cell Preparation Center National Network:
By laying out a "cell therapy expressway network" that can meet the clinical needs including the large-scale production of clinical demand side and also the advanced technology provider side timely, it provides an innovative public technology for clinical transformation of cell therapy technology Platform and infrastructure. It has built and achieved outstanding achievements in Shenzhen, Jiangsu, Guizhou, Jiangxi, Guangxi and Xinjiang, and provides a new way for China's cell therapy industry to develop.
Strong R&D capability:
Beike Biotechnology is: National high-tech enterprises; International Cell Therapy Association (ISCT) member units; application of 39 stem cell field-related patents, 26 authorized; published more than 100 articles at authoritative magazine at home and abroad, including Cell Stem Cell; commitment to more than 60 government projects at all levels, which 6 are state-level projects (2 are 863 projects*)
Strict quality control system:
Adult stem cell and immune cell preparation system and Jiangsu stem cell bank have passed the ISO9001 quality management system certification; has the industry's first access to China National Accreditation Board for Conformity Assessment (CNAS) accreditation testing laboratory qualification; is the first recognized member in mainland China through the (ISCT); the first certified unit in mainland China through the world's advanced blood transfusion and cell therapy technology alliance (AABB).